Search results
Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
Zacks via Yahoo Singapore Finance· 19 hours agoNon-cap weighted indexes try to choose stocks that have a better chance of risk-return performance,...
Should Schwab U.S. Large-Cap Value ETF (SCHV) Be on Your Investing Radar?
Zacks via Yahoo Singapore Finance· 19 hours agoAnnual operating expenses for this ETF are 0.04%, making it the least expensive products in the ...
Should iShares MSCI USA Value Factor ETF (VLUE) Be on Your Investing Radar?
Zacks via Yahoo Singapore Finance· 19 hours agoAnnual operating expenses for this ETF are 0.15%, making it one of the least expensive products in...
Should Schwab 1000 Index ETF (SCHK) Be on Your Investing Radar?
Zacks via Yahoo Singapore Finance· 19 hours agoAnnual operating expenses for this ETF are 0.05%, making it one of the least expensive products in...
Is FlexShares International Quality Dividend ETF (IQDF) a Strong ETF Right Now?
Zacks via Yahoo Singapore Finance· 19 hours agoLower cost products will produce better results than those with a higher cost, assuming all other...
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Zacks via Yahoo Singapore Finance· 19 hours agoAnnual operating expenses for this ETF are 0.70%, making it one of the most expensive products in...
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks via Yahoo Singapore Finance· 19 hours agoLower cost products will produce better results than those with a higher cost, assuming all other...
Should You Invest in the Fidelity MSCI Utilities Index ETF (FUTY)?
Zacks via Yahoo Singapore Finance· 19 hours agoLower cost products will produce better results than those with a higher cost, assuming all other...
Biden admin opens line with crypto industry amid icy relations
The Hill via Yahoo News Singapore· 20 hours agoThe Biden administration opened a line with the cryptocurrency industry Wednesday, as the White...
Trending tickers: Tesla, Nvidia, Pfizer and Superdry
Yahoo Finance UK· 21 hours agoMikael Dolsten, Pfizer’s outgoing chief scientific officer, said that danuglipron “has demonstrated good efficacy in a twice-daily formulation, and we...